Small Biotech Company With Complex, Innovative Cell Immunotherapy in Oncology Executes Successful Phase Ib Clinical Trial Across Multiple Sites

Client Challenge

invIOs is an innovation-driven biotech company that develops first-in-class cell immunotherapy in oncology. The company needed to execute a Phase Ib multicenter clinical trial. Each patient required individualized manufacturing, release, and delivery of the drug product, creating a tightly coupled dependency between drug product manufacturing timelines and clinical site readiness. invIOs wanted to initiate and complete the trial efficiently, ensure the timely treatment of patients, and generate high-quality clinical data to support further development.

invIOs selected Alira Health based on its deep expertise in innovative trial design, including Bayesian methods, strong experience in advanced therapy logistics, and end-to-end execution within a single operating model.

Our Approach

The invIOs team sought help to design an innovative, adaptive Bayesian trial, manage complex supply chain and site logistics, provide close site engagement and proactive monitoring, and ensure tight, end-to-end project management. A flexible, data-driven trial design combined with strong operational control was critical to minimizing delays and enabling timely, informed decision-making, given the complexity and novelty of the therapy.

The Alira Health CRO team, which included experts in clinical operations, biostatistics, and project management, executed on the following critical actions:

• Applied advanced Bayesian statistical design alongside tailored operational frameworks to support the complexity of the immunotherapy trial
• Collaborated closely with manufacturing partners to align product release timelines with clinical site needs
• Established robust logistics to enable just-in-time delivery of patient-specific treatments to sites
• Maintained high-touch site engagement and proactive monitoring to ensure consistent protocol adherence
• Implemented proactive risk management processes to enable rapid identification and resolution of issues

Outcomes

Alira Health delivered a fully integrated clinical trial execution solution, combining an advanced Bayesian trial design tailored to early-phase immunotherapy, intensive site engagement and monitoring, coordination of drug product manufacturing and delivery logistics, and end-to-end project management.

This integrated approach enabled the efficient execution of a highly complex Phase I cell immunotherapy trial, ensuring alignment between manufacturing, logistics, and clinical site operations.

Key outcomes included:

• Accelerated trial setup and initiation timelines despite the complexity of patient-specific therapy
• High protocol adherence across sites, supported by proactive monitoring and engagement
• Efficient coordination of manufacturing and delivery processes, reducing the risk of treatment delays
• Timely clinical study report finalization to support subsequent development decisions

The client expressed high satisfaction with Alira Health’s performance, highlighting responsiveness, flexibility, and expertise.

Key Success Factors

The Alira Health CRO team integrated trial design, clinical operations, and complex supply chain logistics within a single, coordinated execution model, enabling the successful delivery of the study. Strong project management ensured close alignment across all stakeholders through clear communication, tight coordination, and rapid resolution of operational challenges.

In addition, the team’s deep understanding of patient-specific immunotherapies and early-phase trial requirements enabled effective anticipation and management of the unique risks associated with manufacturing, delivery, and site execution.